Quantcast

Industry news that matters to you.  Learn more

Circulating Tumor Cells Can Provide ‘Real-time’ Information on Patient’s Current Disease State

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

Detection of Key Epigenetic Biomarkers

Epigenetics refers to the study of heritable changes in genome function that occur without a change in the primary DNA sequence of an organism. One such change is DNA methylation, most frequently characterized by an enzymatic modification at the fifth position of cytosine (5-mC), present abundantly in the context of CpG dinucleotides. The formation and maintenance of 5-mC is catalyzed by cellular DNA (cytosine-5) methyltransferases (DNMTs).

OncoMethylome Sciences Signs Agreement for the Potential Use of its Technology Platform in GlaxoSmithKline Biologicals Immunotherapy Development Program

OncoMethylome Sciences, a leading molecular diagnostics company, announced today that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.

Sophic Wins $750K in NCI Funding

Sophic Systems Alliance has reeled in a $750,000 grant from the National Cancer Institute to continue development of its Sophic Cancer Biomarker KnowledgeBase (Scan-Mark), which will be used in personalized cancer research.

Neurogenetic Pharmaceuticals Announces Studies Showing its Proprietary Compound Reduces Brain Plaques Associated with Alzheimer’s Disease

In the Sept 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer’s disease (AD) in a transgenic mouse model. The study further demonstrates that following chronic treatment with the gamma secretase modulator (GSM) compound from NGP, the mice were devoid of gastrointestinal side effects, an adverse finding commonly associated with gamma secretase inhibitors (GSIs).